Zacks Investment Research
13 Aug 2026, 14:41 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Halozyme Therapeutics (HALO) has achieved a year-to-date gain of 51.3%, significantly outperforming its medical sector peers who averaged 3.2%. — Strong price momentum and relative strength often attract further institutional interest and trend-following buyers.
+0.40The Zacks Consensus Estimate for Halozyme Therapeutics' full-year earnings has increased by 3.4% over the past quarter. — Upward earnings revisions are a primary indicator of improving fundamental health and potential for future price appreciation.
+0.30Brookdale Senior Living (BKD) has seen its consensus EPS estimate for the current year increase by 160% over the past three months. — A massive revision in earnings expectations suggests a significant positive shift in the company's projected profitability.
+0.30Continue reading
6 related stories
Search tags
Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) both currently hold a Zacks Rank of #2 (Buy). — A high analyst/model rank serves as a bullish signal for short-to-medium term investors.
+0.20Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
